Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Celsius Holdings, Inc. (CELH) vs GSK plc (GSK) Price & Performance

Celsius Holdings, Inc.Trade

Price performance (Past 24H)

Key statistics

Celsius Holdings, Inc. vs GSK plc — how do they compare? Celsius Holdings, Inc. trades at $27.6 (market cap $7.11B), while GSK plc trades at $50.37 (market cap $102.60B). The key difference: GSK plc is far larger — about 14.4× Celsius Holdings, Inc.'s market cap, and GSK plc pays a 3.57% dividend while Celsius Holdings, Inc. pays none. Which is the better fit depends on your goals.

CELHGSK
Market Cap
$7.11B$102.60B
Sector
Consumer StaplesHealth
52-Week High
$64.86$61.18
52-Week Low
$23.77$38.22
Enterprise Value
$8.90B$123.04B
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Celsius Holdings, Inc.

CELH trades at $27.37, up 0.59% on the day, but its technical outlook is bearish with key support at $26. Revenue growth remains strong, reaching $2.52B in 2025, though net income margins have compressed to 4.24%. The company faces headwinds from a recent earnings miss and core brand weakness, but maintains a robust 95.65% analyst buy rating with a $44.08 consensus price target.

The stock offers significant upside potential based on analyst targets, but risks include execution challenges, intense competition, and margin pressure. Investor sentiment is cautious due to slowing growth and leadership changes, yet the long-term growth story, supported by the PepsiCo partnership, remains intact for patient investors.

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Celsius Holdings, Inc.

Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.

Read more on CELH

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK